Bimekizumab

Indication

for treating moderate to severe plaque psoriasis (TA 723).

Red

Brand:

Nice TA:

723

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Skin

1.1 Bimekizumab is recommended as an option for treating plaque psoriasis in adults, only if:

the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and
the company provides the drug according to the commercial arrangement.

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 18 - Oct - 2021